Phase 2
N=28
Testosterone and Myocardial Perfusion in Coronary Heart Disease (CHD)
Coronary Heart Disease
Bottom Line
View on ClinicalTrials.gov: NCT00239590 ↗Enrolled (actual)
28
Serious AEs
1.8%
Results posted
Sep 2019
Primary outcome: Primary: Myocardial Perfusion — 1.83; 1.52 myocardial perfusion index
Study Design & Population
- Study type
- Interventional
- Phase
- Phase 2
- Interventions
- Testosterone undecanoate (Drug)
- Age
- Adult, Older Adult · 35+ yrs
- Sex
- Male
- Sponsor
- Imperial College London
- Primary completion
- Apr 2004
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Myocardial Perfusion |
1.83; 1.52 | — |
| SECONDARY Endothelial Function |
76.5; 79.4 | — |
Summary
Testosterone has traditionally been regarded as a risk factor for heart disease due to the fact that males have a higher incidence of this disease than women, at least until the menopause. However recent studies have shown that men with low levels of testosterone may be at an increased risk of developing coronary heart disease (furring up of the blood vessels supplying blood to the heart). Our group has demonstrated a relaxing effect of testosterone in isolated animal coronary arteries (blood vessels supplying blood to the heart). We have shown that short-term testosterone administration can increase coronary artery and brachial artery (blood vessel in the arm) blood flow and can decrease the lack of blood supply to the heart muscle in men with coronary artery disease. These findings indicate a need for similar but longer-term studies to investigate the possible beneficial effects of longer-term testosterone therapy on the heart and blood vessels. Should this treatment be shown to be beneficial to men with coronary artery disease it may be a useful additional therapy for men with the furring up of arteries in the heart and the resulting angina.
Aim To investigate our hypothesis that testosterone can beneficially affect myocardial perfusion, vascular reactivity, metabolic risk factors for coronary heart disease and improve quality of life in men with low plasma testosterone levels and coronary heart disease.
Eligibility Criteria
Inclusion Criteria
- Men
- Aged 35 to 75 years
- Angiographically proven coronary artery disease (70 percent lesion in at least one major coronary artery, or major branch), including patients post-coronary artery bypass graft (CABG) and percutaneous coronary intervention (PCI)
- Plasma testosterone less than or equal to 12 nmol/l
- Normal prostate specific antigen (PSA; normal range 0 - 4 g/l)
- Willing to give written informed consent
Exclusion Criteria
- Significant arrhythmia, particularly those which would affect interpretation of the ST-segment of the ECG
- Treatment with digitalis
- Treatment with testosterone or similar hormonal therapy
- Thoracic or abdominal surgery within the previous 3 months
- Haemoglobin >16 g/dL
- Haematocrit >50 percent
- History of hormone-dependent cancer such as prostate or breast cancer
- Hypercalcaemia
- Nephrosis
- Pacemaker or automated implantable cardiac defibrillator
- Implanted ferromagnetic arterial clips
- Left ventricular hypertrophy
- New York Heart Association (NYHA) III or IV functional class
- Intolerance of confined spaces
- Previous allergic reaction to Gadolinium
- Participation in another research study within the previous 60 days
- Unwilling to give written informed consent
Data sourced from ClinicalTrials.gov (NCT00239590). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.